University - Industry collaborations: Models, drivers and cultures

Swiss Medical Weekly

Volumn 145, Issue , 2015, Pages

  Ehrismann, Dominic ^a   Patel, Dhavalkumar D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

academia; alliance; biomedical; collaboration; industry; innovation; model; organisational culture; pharmaceutical; university

Indexed keywords

BASIC RESEARCH; DECISION MAKING; DRUG INDUSTRY; ENVIRONMENTAL CHANGE; HEALTH CARE COST; HUMAN; INVENTION; INVESTMENT; MEDICAL RESEARCH; ORGANIZATION; PATENT; PROBLEM SOLVING; QUALITY CONTROL; REVIEW; REWARD; RISK; UNIVERSITY HOSPITAL; COOPERATION; ORGANIZATION AND MANAGEMENT; PUBLIC RELATIONS; UNIVERSITY;

BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; DRUG INDUSTRY; HUMANS; INTERINSTITUTIONAL RELATIONS; ORGANIZATIONAL CULTURE; UNIVERSITIES;

EID: 84928978237     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2015.14086     Document Type: Review

References (21)

1. Herper M. The Truly Staggering Cost Of Inventing New Drugs. Forbes 2012 February 10, 2012.
2. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959-68.
3. IFPMA. The Pharmaceutical Industry and Global Health, Facts and Figures 2012. Geneva: IFPMA; 2012.
4. Dasgupta P, David PA. Toward a New Economics of Science. Res Policy. 1994;23:487-521.
5. D'Este P, Perkmann M. Why do academics engage with industry? The entrepreneurial university and individual motivations. J Technol Transfer. 2011;36:316-39.
6. Owen-Smith J, Powell WW. To patent or not: Faculty decisions and institutional success at technology transfer. J Technol Transfer. 2001;26:99-114.
7. Etzkowitz H. Research groups as "quasi-firms": the invention of the entrepreneurial university. Res Policy. 2003;32:109-21.
8. Lowe RA. Who develops a university invention? The impact of tacit knowledge and licensing policies. J Technol Transfer. 2006;31:415-29.
9. Bruneel J, D'Este P, Salter A. Investigating the factors that diminish the barriers to university-industry collaboration. Res Policy. 2010;39:858-68.
10. Chesbrough H. Open Innovation: The new imperative for creating and profiting from technology. Boston: Harvard Business School Press; 2003.
11. Jones D. Introduction to the Ceedd & externalisation at GSK. 2013.
12. Botschen F, Thunecke M. The Biotechisation of Pharma. www.catenion.com; 2013.
13. Fishburn CS. Uprooting CEEDD. SciBX 2013;6:1-2.
14. Schachter B. Partnering with the professor. Nat Biotechnol. 2012;30:944-52.
15. Patel AC, Coyle AJ. Building a new biomedical ecosystem: Pfizer's Centers for Therapeutic Innovation. Clin Pharmacol Ther. 2013;94:314-6.
16. Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem. 2002;277:20104-12.
17. Ziegler Handschin S. The Friedrich Miescher Institute for Biomedical Research turns 40! Basel: The Friedrich Miescher Institute for Biomedical Research 2010.
18. FMI Report 2011/2012. Basel, Switzerland: Friedrich Miescher Institute for Biomedical Research; 2012.
19. Walther C, Lucht S, Giegerich P. Boehringer Ingelheim Foundation provides extensive support for cutting-edge research at the Johannes Gutenberg University Mainz. Mainz 2009.
20. Mintzberg H. The Structuring of Organisations. Hemel Hempstead/Englewood Cliffs, NJ: Prentice Hall; 1979.
21. Kaplan K. Industrial endeavours. Nature. 2009;461:554-5.